Stefano Fanti
University of Bologna
CancerInternal medicineRadiologyPET-CTPathologyMagnetic resonance imagingOncologyTomographyStage (cooking)Positron emission tomographyBiopsyBiochemical recurrenceLymphomaProstatectomyProstate cancerNuclear medicineIn patientFdg pet ctRadiation therapyMedicine
897Publications
83H-index
17kCitations
Publications 897
Newest
#1Hossein Jadvar (SC: University of Southern California)H-Index: 40
#2Jeremie Calais (University of California, Berkeley)
Last. Michael J. Morris (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 66
view all 16 authors...
Source
#1Beatrice CasadeiH-Index: 11
#2Lisa ArgnaniH-Index: 20
Last. Maria GuarinoH-Index: 18
view all 18 authors...
Large B-cell lymphomas (LBCL) are the most common types of non-Hodgkin lymphoma. Although outcomes have improved thanks to the introduction of rituximab-based chemoimmunotherapy, certain LBCL still represents a challenge because of initial resistance to therapy or recurrent relapses. Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are second-generation autologous CD19-targeted chimeric antigen receptor (CAR) T-cell therapies approved for patients with relapsed/refractory (R/R) ...
Source
#1Andrea Paccagnella (UNIBO: University of Bologna)H-Index: 1
#2Andrea FarolfiH-Index: 8
Last. Stefano FantiH-Index: 83
view all 6 authors...
Source
#1Luca BorianiH-Index: 14
#2Eleonora ZampariniH-Index: 8
Last. Cristina NanniH-Index: 54
view all 10 authors...
Spondylodiscitis is an infectious process which requires numerous health care professionals in order to be clearly diagnosed and eventually, successfully treated. It implies a variety of microbiological agents and condition; during the diagnostic workup it is difficult to correctly identify them, and the clinician has to rapidly choose the most correct treatment, in order to avoid permanent injuries to the patient. In this context it comes our review work: based on current guidelines and literat...
Source
#1Boris HadaschikH-Index: 56
#2Stefano FantiH-Index: 83
Last. Robert WapenaarH-Index: 4
view all 11 authors...
Source
#1Elisa Lodi RizziniH-Index: 2
#2Andrea RepaciH-Index: 11
Last. Fabio MonariH-Index: 9
view all 10 authors...
Background: As reported in the literature, [18F]-fluorodeoxyglucose positron emission tomography/computed tomography ([18F]-FDG PET/CT) provides useful qualitative and semi-quantitative data for the prognosis of advanced differentiated thyroid cancer. Instead, there is a lack of data about the real clinical impact of 18F-FDG PET/CT on the choice of the more effective therapeutic approach for advanced differentiated thyroid cancer (DTC) that starts to lose iodine avidity. The primary aim of this ...
Source
#1Matteo SerenariH-Index: 10
#2Alberta CappelliH-Index: 16
Last. Rita GolfieriH-Index: 47
view all 11 authors...
Hepatocellular carcinoma (HCC) with portal vein tumoral thrombosis (PVTT) represents a major concern especially in the field of deceased donor liver transplantation (DDLT). However, when receiving transarterial radioembolization (TARE), a considerable percentage of such patients are able to achieve a radiologic complete response with adequate survival rates. In this pilot prospective study, we evaluated the effect of TARE in downstaging HCC patients with PVTT to meet criteria for DDLT. Between M...
Source
#1Farshad Moradi (Stanford University)H-Index: 20
#2Andrea FarolfiH-Index: 8
Last. Andrei Iagaru (Stanford University)H-Index: 37
view all 4 authors...
Abstract null null The role of molecular imaging in initial evaluation of men with presumed or established diagnosis of prostate cancer and work up of biochemical recurrence and metastatic disease is rapidly evolving due to superior diagnostic performance compared to anatomic imaging. However, variable tumor biology and expression of transmembrane proteins or metabolic alterations poses a challenge. We review the evidence and controversies with emphasis on emerging PET radiopharmaceuticals and e...
Source
#1Nicholas G. Zaorsky (Penn State Cancer Institute)H-Index: 28
#2Jeremie Calais (UCLA: University of California, Los Angeles)H-Index: 20
Last. Amar U. Kishan (UCLA: University of California, Los Angeles)H-Index: 19
view all 7 authors...
More than 40% of men with intermediate-risk or high-risk prostate cancer will experience a biochemical recurrence after radical prostatectomy. Clinical guidelines for the management of these patients largely focus on the use of salvage radiotherapy with or without systemic therapy. However, not all patients with biochemical recurrence will go on to develop metastases or die from their disease. The optimal pre-salvage therapy investigational workup for patients who experience biochemical recurren...
Source
Source